UK markets closed
  • NIKKEI 225

    28,966.01
    -1,202.29 (-3.99%)
     
  • HANG SENG

    28,980.21
    -1,093.99 (-3.64%)
     
  • CRUDE OIL

    62.33
    +0.83 (+1.35%)
     
  • GOLD FUTURES

    1,735.80
    +7.00 (+0.40%)
     
  • DOW

    30,932.37
    -469.63 (-1.50%)
     
  • BTC-GBP

    32,706.51
    -730.56 (-2.18%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • ^IXIC

    13,192.35
    +72.95 (+0.56%)
     
  • ^FTAS

    3,702.40
    -86.34 (-2.28%)
     

Compass Therapeutics to Participate in the B. Riley Securities Virtual Oncology Investor Conference

·2-min read

Compass Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer of Compass Therapeutics, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference.

The Compass presentation will be live webcast at 10:30 a.m. EST on January 21, 2021. The presentation will be open to registered conference attendees, institutional investors and investor relations professionals, who may register to view the live webcast at https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup. After completion of the event, a replay of the presentation will be publicly available under the "Investors – Events and Presentations" tab on the Compass website at www.compasstherapeutics.com.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, and is currently being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. Compass is also progressing several preclinical assets including a novel class of NK cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005222/en/

Contacts

Media
Compass Therapeutics, Inc.
Garrett Winslow, Senior Vice President and Head of Legal Affairs
media@compasstherapeutics.com
617-500-8099